 LEXINGTON, Mass., May 11, 2021 PRNewswire -- Pulmatrix, Inc. NASDAQ: PULM, a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSETM technology, today reports its first quarter 2021 financial results and provides a business update. 